Keryx Biopharma (KERX) Receives Orphan Drug Designation From the FDA
July 14, 2010 at 12:36 PM EDT
Shares of drug developer Keryx Biopharmaceuticals Inc. (KERX) spiked 17 percent to $4.18 for the biggest gain in the Russell 2000 Index. The co. said its experimental cancer drug, KRX-0401 (perifosine), received orphan drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting [...]
